Citi puts Amarin and Sarepta on top five SMid cap biotech pick list

Citi analyst Joel Beatty removed The Medicines Co. (MDCO) and Minerva (NERV) from his top five Buy-rated stocks in SMid cap Biotech. These stocks are up 34% and 28%, respectively, since the analyst established them as among his top five Buy-rated stocks in July. Beatty replaced The Medicines Co. and Minerva with Amarin (AMRN) and Sarepta Therapeutics (SRPT). His top five buys are now Amarin, Eloxx Pharmaceuticals (ELOX), NGM Biopharmaceuticals (NGM), PTC Therapeutics (PTCT) and Sarepta. He wants to own Amarin into the November FDA panelmeeting, believing it will be "innocuous" and lead to a risk reduction label for Vascepa. On Sarepta, Beatty thinks the recent share pullback is overblown, and he reiterates his thesis that "although there will likely be some minor bumps on the road," the company will ultimately win the Image result for Duchenne muscular dystrophy gene therapy race